Pharmacogenetics: Point-of-care genetic testing--a new frontier explored

Nat Rev Cardiol. 2012 May 1;9(6):315-6. doi: 10.1038/nrcardio.2012.63.
No abstract available

Publication types

  • News

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Genetic Testing / methods*
  • Genotype
  • Humans
  • Patient Selection
  • Pharmacogenetics*
  • Phenotype
  • Platelet Activation / drug effects
  • Platelet Aggregation Inhibitors / pharmacokinetics*
  • Point-of-Care Systems*
  • Precision Medicine
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine